IN THE CLAIMS

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

1. (canceled)

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (currently amended) A method for the treatment of malaria which comprises administering to a patient in need of such treatment a compound of formula I:



wherein,

R^5 is hydrogen;

R^{1a} and R^1 independently are tert-butyl, halo, C_{1-6} alkoxy, C_{3-10} cycloalkyl, C_{6-10} aryl, or trihalovinyl, wherein said aryl is optionally substituted with 1-3 groups of R^a;

each R^2 is hydrogen; ~~hydrogen, C_{1-6} alkyl, or C_{3-10} cycloalkyl; or alternatively both R^2 groups are taken together with any intervening atoms to form a heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO_2, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;~~

~~R^{2a} is hydrogen or C_{1-6} alkyl;~~

R^3 and R^{3a} are independently hydrogen, halo, C_{1-6} alkyl, C_{3-10} cycloalkyl, or C_{6-10} aryl, wherein said aryl and alkyl are each optionally substituted with 1-3 groups of R^a; ~~or~~

~~R^3 and R^{3a} are taken together with any intervening atoms to form a 3 to 7 membered carbocyclic or heterocyclic ring saturated or unsaturated, said heterocyclic ring containing 1-2 heteroatoms independently chosen from O, C(O), S, SO, SO2, N, or NR^{2a} and optionally substituted by 1-3 R^a groups;~~

R^4 is hydrogen; ~~hydrogen, halo, C_{1-6} alkyl, or trihaloalkyl;~~

R^a represents C_{1-6} alkoxy, C_{1-6} alkyl, CF_3, nitro, amino, cyano, C_{1-6} alkylamino, or halogen; and

n represents 1-3;

or a pharmaceutically acceptable salt, enantiomer, or diastereomer thereof.

10. (currently amended) A method according to claim 9 wherein the compound is selected from the group consisting of:
2-aminomethyl-5-tert-butyl-3-phenylphenol,
2-aminomethyl-5-tert-butyl-3-(4-methylphenyl)phenol,
~~3,5-di-tert-butyl-2-[(ethylamino)methyl]phenol,~~
~~3,5-di-tert-butyl-2-[1-(ethylamino)ethyl]phenol,~~
~~3,5-di-tert-butyl-2-[(methylamino)methyl]phenol,~~
~~3,5-bis(trichlorovinyl)-2-[(ethylamino)methyl]phenol,~~
~~3,5-di-tert-butyl-2-[(propylamino)methyl]phenol,~~
~~3,5-di-tert-butyl-2-[(butylamino)methyl]phenol,~~

~~3,5-di-tert-butyl-2-[(cyclohexylamino)methyl]phenol,~~
~~3,5-di-tert-butyl-2-[(hexylamino)methyl]phenol,~~
2-(aminomethyl)-3,5-di-tert-butylphenol,
2-(2-aminoethyl)-3,5-di-*tert*-butylphenol,
2-(aminomethyl)-3,5-bis(trichlorovinyl)phenol,
2-(1-aminoethyl)-3,5-di-*tert*-butylphenol,
~~3,5-di-*tert*-butyl-2-[1-(ethylamino)ethyl]phenol,~~
~~3,5-di-*tert*-butyl-2-[(propylamino)methyl]phenol,~~
and pharmaceutically acceptable salts thereof.

11. (currently amended) A method according to claim 9 wherein a second anti-malarial agent is administered and said second anti-malarial agent selected from the group consisting of Chloroquine, Fansidar, Amodiaquine, Quinine, Halofantrine, Mefloquine, Artemether/Artesunate and Malarone.

12. (previously presented) A method according to claim 9, wherein in the compound of formula I or a pharmaceutically acceptable salt thereof, R^{1a} and R^{1} independently are tert-butyl, 1,2,2-trichlorovinyl, or phenyl.

13. (currently amended) A method according to claim 9, wherein in the compound of formula I or a pharmaceutically acceptable salt thereof, ~~R^{2} is hydrogen or C_{1-4} alkyl; and~~ n is 1.

14. (currently amended) A method according to claim 9, wherein in the compound of formula I or a pharmaceutically acceptable salt thereof, R^{1a} and R^{1} independently are tert-butyl, 1,2,2-trichlorovinyl, or phenyl; ~~R^{2} is hydrogen or C_{1-4} alkyl;~~ and n is 1.

15. (previously presented) A method according to claim 14, wherein in the compound of formula I or a pharmaceutically acceptable salt thereof, R^{1a} and R^{1} are tert-butyl; and R^{2} is hydrogen.

16. (previously presented) A method according to claim 15, wherein the compound of formula I is 2-(aminomethyl)-3,5-di-tert-butylphenol or a pharmaceutically acceptable salt thereof.

17. (previously presented) A method according to claim 16, wherein the compound of formula I is 2-(aminomethyl)-3,5-di-tert-butylphenol hydrochloride.

18. (currently amended) A method according to claim 16, wherein a second anti-malarial agent is administered and said second anti-malarial agent selected from the group consisting of Chloroquine, Fansidar, Amodiaquine, Quinine, Halofantrine, Mefloquine, Artemether/Artesunate and Malarone.

19. (previously presented) A method according to claim 16, wherein the compound or its pharmaceutically acceptable salt is a component in a pharmaceutical composition that also comprises a pharmaceutically acceptable carrier.

20. (previously presented) A method according to claim 9, wherein the compound of formula I or its pharmaceutically acceptable salt is a component in a pharmaceutical composition that also comprises a pharmaceutically acceptable carrier.

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)